News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
232,013 Results
Type
Article (5093)
Company Profile (24)
Press Release (226896)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (82251)
Career Advice (463)
Deals (15055)
Drug Delivery (8)
Drug Development (19075)
Employer Resources (30)
FDA (3683)
Job Trends (3909)
News (120183)
Policy (7514)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (293)
Accelerated approval (6)
Adcomms (4)
Allergies (14)
Alliances (14810)
ALS (38)
Alzheimer's disease (295)
Antibody-drug conjugate (ADC) (40)
Approvals (3783)
Artificial intelligence (80)
Autoimmune disease (27)
Automation (5)
Bankruptcy (97)
Best Places to Work (2865)
Biosimilars (32)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (7)
Breast cancer (101)
Cancer (886)
Cardiovascular disease (61)
Career advice (395)
Career pathing (3)
CAR-T (64)
CDC (2)
Cell therapy (166)
Cervical cancer (5)
Clinical research (16683)
Collaboration (353)
Compensation (371)
Complete response letters (8)
COVID-19 (312)
CRISPR (13)
C-suite (338)
Cystic fibrosis (28)
Data (1325)
Denatured (1)
Depression (21)
Diabetes (78)
Diagnostics (2115)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (31)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (35)
Earnings (42738)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (39135)
Executive appointments (424)
FDA (4421)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (340)
Gene editing (24)
Generative AI (5)
Gene therapy (102)
GLP-1 (144)
Government (423)
Guidances (197)
Healthcare (5047)
HIV (10)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (39)
Immuno-oncology (7)
Indications (16)
Infectious disease (338)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (32)
Interviews (53)
IPO (7880)
IRA (3)
Job creations (1122)
Job search strategy (361)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (106)
Leadership (5)
Legal (2337)
Liver cancer (21)
Longevity (2)
Lung cancer (92)
Lymphoma (70)
Machine learning (3)
Management (10)
Manufacturing (139)
MASH (50)
Medical device (3919)
Medtech (3929)
Mergers & acquisitions (7580)
Metabolic disorders (214)
Multiple sclerosis (18)
NASH (6)
Neurodegenerative disease (54)
Neuropsychiatric disorders (12)
Neuroscience (540)
NextGen: Class of 2026 (1674)
Non-profit (730)
Now hiring (5)
Obesity (84)
Opinion (32)
Ovarian cancer (26)
Pain (26)
Pancreatic cancer (38)
Parkinson's disease (50)
Partnered (6)
Patents (51)
Patient recruitment (96)
Peanut (6)
People (25219)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (4995)
Phase 2 (7226)
Phase 3 (5789)
Pipeline (1962)
Policy (17)
Postmarket research (625)
Preclinical (1947)
Press Release (66)
Prostate cancer (57)
Psychedelics (3)
Radiopharmaceuticals (109)
Rare diseases (179)
Real estate (1886)
Recruiting (8)
Regulatory (5537)
Reports (17)
Research institute (308)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (1)
RSV (2)
Schizophrenia (49)
Series A (53)
Series B (54)
Sickle cell disease (10)
Special edition (1)
Spinal muscular atrophy (33)
Sponsored (5)
Startups (1017)
Stomach cancer (1)
Supply chain (13)
Tariffs (7)
The Weekly (1)
Vaccines (80)
Venture capital (9)
Weight loss (29)
Women's health (6)
Date
Last 7 days (146)
Last 30 days (538)
Last 365 days (8884)
2026 (784)
2025 (9036)
2024 (11030)
2023 (13193)
2022 (18659)
2021 (19679)
2020 (18240)
2019 (13205)
2018 (10205)
2017 (10002)
2016 (9157)
2015 (12118)
2014 (9588)
2013 (7708)
2012 (8331)
2011 (8796)
2010 (8635)
Location
Africa (186)
Alabama (19)
Alaska (2)
Arizona (74)
Arkansas (1)
Asia (11783)
Australia (1690)
California (3541)
Canada (1138)
China (167)
Colorado (143)
Connecticut (162)
Delaware (70)
Europe (25487)
Florida (541)
Georgia (67)
Idaho (24)
Illinois (161)
India (14)
Indiana (105)
Iowa (9)
Japan (164)
Kansas (36)
Kentucky (17)
Louisiana (8)
Maine (51)
Maryland (352)
Massachusetts (2803)
Michigan (104)
Minnesota (201)
Mississippi (1)
Missouri (31)
Montana (17)
Nebraska (12)
Nevada (46)
New Hampshire (16)
New Jersey (1018)
New Mexico (5)
New York (814)
North Carolina (479)
North Dakota (4)
Northern California (1854)
Ohio (116)
Oklahoma (5)
Oregon (6)
Pennsylvania (597)
Puerto Rico (1)
Rhode Island (19)
South America (279)
South Carolina (17)
Southern California (1304)
Tennessee (61)
Texas (480)
United States (12328)
Utah (111)
Virginia (84)
Washington D.C. (17)
Washington State (297)
West Virginia (2)
Wisconsin (57)
Wyoming (1)
232,013 Results for "durect corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
September 12, 2025
·
7 min read
Press Releases
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
August 27, 2025
·
6 min read
Press Releases
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
July 30, 2025
·
11 min read
Business
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
DURECT Corporation announced financial results for the three months ended March 31, 2024 and provided a business update.
May 13, 2024
·
11 min read
FDA
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH).
May 21, 2024
·
9 min read
Business
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
DURECT Corporation announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
March 27, 2024
·
12 min read
Business
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation, a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, announced that the company will report its first quarter financial results on Monday, May 13, 2024.
May 7, 2024
·
4 min read
Business
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
DURECT Corporation announced that the company will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024.
March 20, 2024
·
4 min read
Business
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
DURECT Corporation announced financial results for the three months ended September 30, 2023 and provided a corporate update.
November 13, 2023
·
13 min read
Biotech Bay
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
DURECT Corporation announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024.
February 7, 2024
·
4 min read
1 of 23,202
Next
